Evidence map›Paper›PMID 22100352›Full record

ArticleJournal of molecular and cellular cardiology2012

Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.

Cordelia J Barrick, Patricia M Lenhart, Ryan T Dackor, Elizabeth Nagle, Kathleen M Caron

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Dawn of a New RAMPage.Trends in pharmacological sciences · 2020
    Review
  3. Review
  4. Lymphatic Function and Dysfunction in the Context of Sex Differences.ACS pharmacology & translational science · 2019
    Review
  5. Article
  6. Article
  7. Article
  8. Cohort of estrogen-induced microRNAs regulate adrenomedullin expression.American journal of physiology. Regulatory, integrative and comparative physiology · 2016
    Article
  9. Article
  10. Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.Annual review of pharmacology and toxicology · 2016
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cordelia J BarrickDepartment of Cell & Molecular Physiology, The University of North Carolina, Chapel Hill, NC 27599, USA.
Patricia M Lenhart
Ryan T Dackor
Elizabeth Nagle
Kathleen M Caron
University of North Carolina at Chapel Hill · US

Funding

Pre-doctoral Training Program in Integrative Vascular BiologyT32HL069768 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christopher P. Mack · 2002 to 2026
$9.7M
Adrenomedullin Signaling in Vascular DevelopmentR01HL091973 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARON, KATHLEEN M · 2008 to 2011
$1.4M
RAMP3 Modulation of GPER1 Function in Cardiovascular DiseaseF30HL104778 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LENHART-PENDERGRASS, PATRICIA MARIE · 2010 to 2014
$151k
NHLBI NIH HHS F30 HL104778NHLBI NIH HHS HL091973NHLBI NIH HHS R01 HL091973
6 · The paper itself

Abstract

Sex differences exist in the hypertrophic response, cardiac remodeling, and transition to heart failure of hypertensive patients, and while some of these differences are likely influenced by estrogen, the genetic pathways downstream of estrogen that impact on cardioprotection have yet to be fully elucidated. We have previously shown that the cardioprotective effects of adrenomedullin (AM), an emerging clinical biomarker for cardiovascular disease severity, vary with sex in mouse models. AM signaling during cardiovascular stress is strongly modulated by receptor activity-modifying protein 3 (RAMP3) via its interaction with the G protein-coupled receptor calcitonin receptor-like receptor (CLR). Like AM, RAMP3 expression is potently regulated by estrogen, and so we sought to determine the consequences of genetic Ramp3 loss on cardiac adaptation to chronic hypertension, with a particular focus on characterizing potential sex differences. We generated and bred RAMP3(-/-) mice to RenTgMK mice that consistently display severe angiotensin II-mediated CV disease and compared CV disease progression in RenTgMK to that of RenTgMK:RAMP3(-/-) offspring. As expected, RAMP3 gene expression was higher in cardiovascular tissues of RenTgMK mice and more strongly up-regulated in female RenTgMK mice relative to wildtype controls. RAMP3 loss did not affect the development of hypertension or the presence and severity of perivascular and interstitial fibrosis in the left ventricle (LV). However, echocardiography revealed that while RenTgMK mice developed concentric cardiac hypertrophy with sustained systolic function, male RenTgMK:RAMP3(-/-) mice showed evidence of LV chamber dilatation and depressed systolic function, suggestive of cardiac decompensation. Consistent with these measures of heart failure, male RenTgMK:RAMP3(-/-) mice had increased cardiac apoptosis and elevated activation of Akt. These phenotypes were not present in female RenTgMK:RAMP3(-/-) mice. Collectively, these data demonstrate a sex-dependant, cardioprotective role of RAMP3 in the setting of chronic hypertension.

Indexed as

Angiotensin IIAnimalsCardiomegalyCardiovascular DiseasesDisease Models, AnimalFemaleGene ExpressionGene Expression ProfilingGene Knockout TechniquesGenetic Association StudiesHeart FailureHypertensionHypertrophy, Right VentricularKidney DiseasesMaleMiceAngiotensin IIProto-Oncogene Proteins c-aktReceptor Activity-Modifying Protein 3Renin

Identifiers

PMID22100352
PMCPMC3256744
OpenAlexW2050421074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.